免責聲明：本網頁內容不能做為醫師及本協會對個人的正式醫療行為及解說。個人的醫療及解說須以醫療院所正式的診斷及醫療為依據。
站內關鍵字搜尋
| 症狀 | 醫療測試方法 | 測試期別 |
| Neurofibromatosis Type 1 | Drug: Lamotrigine | Phase 2 |
| Cognition | Drug: Placebo | Phase 3 |
| Neurofibromatosis Type 1 | Drug: methylphenidate | Phase 4 |
| ADHD | ||
| Neurofibromatosis Type 1 | Drug: Lovastatin ™ | Phase 2 |
| attention deficits, memory | Device: placebo | |
| Neurofibromatosis Type 1 | Drug: Sirolimus, Rapamycin | Phase 2 |
| Progressive plexiform neurofibroma(s) | ||
| Neurofibromatosis Type 1 | Drug: pirfenidone | Phase 1 |
| Precancerous Condition | ||
| Plexiform Neurofibroma Associated With Neurofibromatosis Type 1 | Drug: Everolimus | Phase 4 |
| NF1 | Drug: Cabozantinib | Phase 2 |
| Neurofibromatosis | ||
| Plexiform Neurofibromas | ||
| Neurofibromatosis Type I | Drug: Nexavar (BAY 43-9006) (Sorafenib) | Phase 1 |
| Plexiform Neurofibroma | Drug: Toxicity, Pharmacokinetics | |
| Drug: Pharmacodynamics | ||
| Drug: Radiographic Evaluation | ||
| Drug: QOL assessment, Neuropsychological | ||
| Drug: Bony Toxicity |
在本網頁提供的資料僅供參考，並非對醫療上的建議，也不構成上市臨床活動的認可。以上是美國和歐洲的資訊來源所整理的醫療試驗。
李銘仁整理 2015-12-07